Modulari-T Bioscience Announces a Research Collaboration with a Leading Global Biopharmaceutical Company for a Novel In Vivo CAR-T Program

Montreal, Canada– September, 2026 – Modulari-T, a biotechnology company pioneering next-generation in vivo cell therapies for oncology and autoimmune disorders, announces a research collaboration with a global top 10 pharma company on a novel in vivo CAR-T program against an undisclosed solid tumor cancer target.

“We are truly delighted to be collaborating with our esteemed new partner on this exciting project”, said Tanya Borsuk, Ph.D., Chief Executive Officer at Modulari-T.  “Our proprietary MARC and MoVE platforms were built on the premise that an in-depth knowledge of the modular structure and function of native immune receptors is required to unlock the true power of CAR-T technologies.  These technologies offer First- and Best-in-Class opportunities deliver a highly novel programs that surmount the limitations of competitor technologies”

The collaboration is supported by CQDM under the Quantum Leap program.

“CQDM is pleased to have facilitated the establishment of collaborations for Modulari-T by creating beneficial links with the Global Biopharmaceutical community. These links between early-stage Canadian companies and the biopharmaceutical industry are critical for the growth of the Canadian life sciences sector,” said Jesse Paterson, Senior Director, Strategy and Pharmaceutical Alliances.